Improving treatments for dementia with Lewy bodies and Parkinson’s disease-dementia
Synergistic Enhancement of ER proteostasis, trafficking, and lysosomes as treatments for Dementia with Lewy bodies and Parkinson’s disease-dementia
This study is looking into how certain proteins and cell functions are linked to dementia with Lewy bodies and Parkinson’s disease-dementia, hoping to find new ways to help improve memory and daily life for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10936681 on NIH RePORTER |
What this research studies
This research investigates the underlying mechanisms of neurodegeneration in dementia with Lewy bodies and Parkinson’s disease-dementia, focusing on the role of a-synuclein aggregation and lysosomal dysfunction. By exploring how these processes contribute to disease progression, the research aims to identify potential therapeutic targets that can enhance protein degradation and trafficking within cells. Patients may benefit from new treatment strategies that address the root causes of their symptoms, potentially improving cognitive function and quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with dementia with Lewy bodies or Parkinson’s disease-dementia.
Not a fit: Patients with other forms of dementia or neurodegenerative diseases unrelated to synucleinopathies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that slow down or halt the progression of dementia with Lewy bodies and Parkinson’s disease-dementia.
How similar studies have performed: Previous research has shown promising results in targeting lysosomal dysfunction and protein aggregation in related neurodegenerative diseases, indicating potential for success in this approach.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Mazzulli, Joseph R — Northwestern University at Chicago
- Study coordinator: Mazzulli, Joseph R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.